Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > CD8+ TiLs and T-cell exhaustion

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 25, 2024 10:08pm

123 Views

Post# 36057724

RE:RE:RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion

Bracelet-1 demonstrated that pelareorep is an effective immunotherapy agent without an immune checkpoint inhibitor AND that pelareorep is more effective than chemotherapy (I.e. paclitaxel).

Consequently ONCY is now able to report that pelareorep is an effective immunotherapy by itself but is synergistically more effective when combined with another I/O agent and/or a chemotherapy agent in a biomarker defined precision I/O combination therapy.

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals